The Cellular Immunology Core is designed to receive and process samples from human subjects in order to evaluate cellular immune responses. Standard operating procedures have been put into place and validated in accordance with ICH Harmonised Tripartite Guidelines [1]. The laboratory itself is run in the spirit of Good Laboratory Practices as outlined by FDA regulations. The facility has appropriately trained research technicians, a quick retrieval system for samples and data. In addition annual reviews of standard operating procedures and employee records have been instituted. This core has supported a number of clinical trials and will be responsible for the cellular immunology in the clinical studies that are outlined in the program project, Project 2/ In addition this core will collaborate with Projects 1, 3 and 4 on the proposed primate studies. Briefly, the program project outlines a plan to investigate new HIV-1 DNA immunotherapy. Project 1 will utilize the SIV infected macaque model to study immunotherapy. Project 2 includes two proposed clinical studies. Project 3 will investigate immune reconstitution and a collaborative effort between Core B and Project 3 will investigate immune reconstitution using MHC class I and class II tetramers specific for humans as detained in this core and in Project 3. Project 4 and this core will collaborate and will investigate CTL escape mutants and the persistence of viral reservoirs. The Core is intimately involved with Project 1. The first clinical study will be a dose-escalating safety and immune responsiveness study of a new plasmid construct containing the gene for IL-15 expression. The second clinical study will assess of the safety and immunostimulatory effects of co-administering the IL-15 construct with the HIV vaccines. The Clinical Immunology Core will perform the following assays: ELISPOT analysis, intracellular staining for IFN-gamma and MHC class I tetramer binding analysis for the clinical studies. The cumulative set of data will provide a comprehensive view of the CD8 and CD4HIV-1 specific responses and how they are enhanced by the various immunotherapy regimens. In addition, the core will collaborate with project 1 for intracellular straining for IFN-gamma in the proposed primate studies. Finally Core B will collaborate with Project 3 on MHC class I and class II tetramers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI048241-01A1
Application #
6544617
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-09-25
Project End
2005-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Villarreal, Daniel O; Wise, Megan C; Siefert, Rebekah J et al. (2015) Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity. Mol Ther 23:1653-62
Morrow, Matthew P; Tebas, Pablo; Yan, Jian et al. (2015) Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther 23:591-601
Villarreal, Daniel O; Svoronos, Nikolaos; Wise, Megan C et al. (2015) Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. Vaccine 33:4313-20
Villarreal, Daniel O; Weiner, David B (2015) IL-33 isoforms: their future as vaccine adjuvants? Expert Rev Vaccines 14:489-92
Tanel, Andre; Fonseca, Simone G; Yassine-Diab, Bader et al. (2009) Cellular and molecular mechanisms of memory T-cell survival. Expert Rev Vaccines 8:299-312
MacGregor, Rob Roy; Boyer, Jean D; Ugen, Kenneth E et al. (2005) Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral ""blips"". Vaccine 23:2066-73
Agadjanyan, Michael G; Chattergoon, Michael A; Holterman, Mark J et al. (2003) Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. J Immunol 171:4311-9
Calarota, Sandra A; Otero, Miguel; Hermanstyne, Keith et al. (2003) Use of interleukin 15 to enhance interferon-gamma production by antigen-specific stimulated lymphocytes from rhesus macaques. J Immunol Methods 279:55-67
MacGregor, Rob Roy; Ginsberg, Richard; Ugen, Kenneth E et al. (2002) T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 16:2137-43